174 related articles for article (PubMed ID: 32803089)
1. ApoB48-Lipoproteins Are Associated with Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome.
Vine DF; Beilin LJ; Burrows S; Huang RC; Hickey M; Hart R; Proctor SD; Mori TA
J Endocr Soc; 2020 Aug; 4(8):bvaa061. PubMed ID: 32803089
[TBL] [Abstract][Full Text] [Related]
2. Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents With Polycystic Ovary Syndrome.
Vine DF; Wang Y; Jetha MM; Ball GD; Proctor SD
J Clin Endocrinol Metab; 2017 Mar; 102(3):970-982. PubMed ID: 27997268
[TBL] [Abstract][Full Text] [Related]
3. ApoB-lipoprotein remnant dyslipidemia and high-fat meal intolerance is associated with markers of cardiometabolic risk in youth with obesity.
Krysa JA; Ball GDC; Vine DF; Jetha M; Proctor SD
Pediatr Obes; 2021 May; 16(5):e12745. PubMed ID: 33150705
[TBL] [Abstract][Full Text] [Related]
4. ApoB48-remnant lipoproteins are associated with increased cardiometabolic risk in adolescents.
Krysa JA; Vine DF; Beilin LJ; Burrows S; Huang RC; Mori TA; Proctor SD
Atherosclerosis; 2020 Jun; 302():20-26. PubMed ID: 32413793
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome.
Vine D; Proctor E; Weaver O; Ghosh M; Maximova K; Proctor S
J Endocr Soc; 2021 Sep; 5(9):bvab114. PubMed ID: 34286169
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Kupreeva M; Diane A; Lehner R; Watts R; Ghosh M; Proctor S; Vine D
Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E16-E33. PubMed ID: 30153063
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
8. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
[TBL] [Abstract][Full Text] [Related]
9. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
Véniant MM; Zlot CH; Walzem RL; Pierotti V; Driscoll R; Dichek D; Herz J; Young SG
J Clin Invest; 1998 Oct; 102(8):1559-68. PubMed ID: 9788969
[TBL] [Abstract][Full Text] [Related]
11. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.
Roe A; Hillman J; Butts S; Smith M; Rader D; Playford M; Mehta NN; Dokras A
J Clin Endocrinol Metab; 2014 May; 99(5):E841-7. PubMed ID: 24512495
[TBL] [Abstract][Full Text] [Related]
12. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
[TBL] [Abstract][Full Text] [Related]
13. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
14. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Demirel F; Bideci A; Cinaz P; Camurdan MO; Biberoğlu G; Yesilkaya E; Hasanoğlu A
Clin Endocrinol (Oxf); 2007 Jul; 67(1):129-34. PubMed ID: 17465999
[TBL] [Abstract][Full Text] [Related]
15. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
[TBL] [Abstract][Full Text] [Related]
16. Elevated remnant lipoproteins may increase subclinical CVD risk in pre-pubertal children with obesity: a case-control study.
Wang Y; Pendlebury C; Dodd MM; Maximova K; Vine DF; Jetha MM; Ball GD; Proctor SD
Pediatr Obes; 2013 Oct; 8(5):376-84. PubMed ID: 23239597
[TBL] [Abstract][Full Text] [Related]
17. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
[TBL] [Abstract][Full Text] [Related]
18. Higher ANGPTL3, apoC-III, and apoB48 dyslipidemia, and lower lipoprotein lipase concentrations are associated with dysfunctional visceral fat in adolescents with obesity.
Rodríguez-Mortera R; Caccavello R; Garay-Sevilla ME; Gugliucci A
Clin Chim Acta; 2020 Sep; 508():61-68. PubMed ID: 32407781
[TBL] [Abstract][Full Text] [Related]
19. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study.
West S; Lashen H; Bloigu A; Franks S; Puukka K; Ruokonen A; Järvelin MR; Tapanainen JS; Morin-Papunen L
Hum Reprod; 2014 Oct; 29(10):2339-51. PubMed ID: 25085801
[TBL] [Abstract][Full Text] [Related]
20. The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.
He H; Feng J; Zhang S; Wang Y; Li J; Gao J; Cong J; Gong Y; Wu X
Front Endocrinol (Lausanne); 2021; 12():773781. PubMed ID: 35069437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
